Aptar Pharma has announced that a new budesonide DPI launched in China by Shanghai Sine Promod Pharmaceutical is the first marketed product to incorporate Aptar's new Twister device. The new 200µg dose budesonide inhaler is available in 30 capsule and 60 capsule versions for the treatment of asthma. In April 2012, Aptar Pharma announced the availability of the … [Read more...] about Shanghai Sine Promod Budesonide DPI incorporates Aptar’s Twister device
Business
Insmed announces public stock offering to support Arikayce development
Insmed Incorporated has announced that it is offering 10 million shares of its common stock at $20.65 per share, which it expects to generate net proceeds of about $194 million. The company says that it will use the money for expenses related to Arikayce inhaled liposomal through commercialization, for further development of INS1009 inhaled treprostinil prodrug … [Read more...] about Insmed announces public stock offering to support Arikayce development
Par launches Nascobal single use cyanocobalamin nasal spray
Par Specialty Pharmaceuticals (formerly called Strativa Pharmaceuticals) has launched a single use version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies, the company said. The FDA approved the single dose, once-a-week product, which is packaged in cartons of four, in June 2014. The company also … [Read more...] about Par launches Nascobal single use cyanocobalamin nasal spray
Discovery Labs restructuring to focus on Aerosurf program
Discovery Laboratories has announced that it will switch its focus from Surfaxin lucinactant intratracheal suspension product to development of its Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The company said that if it is unable to find a partner for Surfaxin, it will "cease the commercialization" of … [Read more...] about Discovery Labs restructuring to focus on Aerosurf program
Pulmatrix to merge with Ruthigen
California-based biopharmaceutical company Ruthigen and inhaled drug developer Pulmatrix have announced a definitive merger agreement under whose terms Pulmatrix will become a wholly-owned subsidiary of Ruthigen. According to the announcement, conversion of Pulmatrix's outstanding debt and equity securities into Ruthigen common stock will account for over 80% of … [Read more...] about Pulmatrix to merge with Ruthigen
Indian patent office revokes Spiriva patent
The Indian patent office has revoked a Boehringer Ingelheim patent for Spiriva on grounds that "applicant have failed to establish any technical advancement or any economic significance of the compound Tiotropium bromide monohydrate over the disclosures of prior art" and that it is not patentable under section 3(d) of the Patents Act. The BI patent, titled … [Read more...] about Indian patent office revokes Spiriva patent
Sandoz launches AirFluSal Forspiro in Portugal and Ireland
Sandoz has launched its AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD in Portugal and Ireland, the company said. AirFluSal is now available in twelve European countries, South Korea, and Mexico. The Portuguese Health Authority approved the DPI in October 2014, and Ireland approved the inhaler in November, 2014. Sandoz Head … [Read more...] about Sandoz launches AirFluSal Forspiro in Portugal and Ireland
AmpliPhi announces $13 million private placement financing
AmpliPhi BioSciences (formerly Targeted Genetics) has announced that it has raised approximately $13,000,000 in a private placement financing that it will use for three development programs. The company's lead candidate, AmpliPhage-001, is an inhaled bacteriophage for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. According to the … [Read more...] about AmpliPhi announces $13 million private placement financing
PMCPA reprimands Chiesi for misleading claims about Fostair
The UK's Prescription Medicines Code of Practice Authority (PMCPA) has reprimanded Chiesi for a misleading and unsubstantiated claim regarding the company's Fostair beclometasone/formoterol inhaler. The authority has published advertisements in the BMJ, The Pharmaceutical Journal, and The Nursing Standard that say, "The Code of Practice Panel reported the company to … [Read more...] about PMCPA reprimands Chiesi for misleading claims about Fostair
Newly launched Turing Pharmaceuticals to develop intranasal ketamine, Syntocinon
Several months after Retrophin announced that it would divest several of its pipeline products, including Syntocinon intranasal oxytocin and intranasal ketamine, to Turing Pharmaceuticals, the latter company has officially announced its launch. Turing Pharmaceuticals is headed by Martin Shkreli, who left Retrophin suddenly after reports of "stock trading … [Read more...] about Newly launched Turing Pharmaceuticals to develop intranasal ketamine, Syntocinon